Develops precision medicines for patients with rare cancers.
Elevation Oncology, Inc., based in New York, New York, is a clinical-stage biopharmaceutical company dedicated to advancing targeted therapeutics for cancer treatment across specific genomic profiles within patient populations.
At the forefront of its pipeline is seribantumab, an anti-HER3 monoclonal antibody currently undergoing Phase II clinical trials as part of the CRESTONE study. This investigational therapy is aimed at treating advanced solid tumors characterized by a neuregulin-1 fusion.
Founded in 2019, Elevation Oncology, Inc. continues to drive innovation in oncology by leveraging precision medicine approaches to address unmet medical needs in cancer treatment. The company's mission is to develop effective therapies tailored to genomic biomarkers, with the potential to improve outcomes for patients with specific types of cancer.